Special Issue on Artificial Intelligence-Driven Precision Oncology

Driven by the booming development of artificial intelligence, multi-omics sequencing, medical image analysis and digital healthcare, modern oncology is stepping into a new era. It is shifting from conventional experience-based diagnosis and treatment to data-supported, intelligent and personalized precision oncology. Serving as a core driving force, AI has greatly boosted clinical oncology development, making remarkable progress in cancer risk assessment, early screening, molecular typing, biomarker exploration, treatment prognosis prediction, clinical auxiliary decision-making and new drug research.

To summarize cutting-edge research and clarify future research trends in this fast-growing discipline, the journal Precision Medication launches a special issue titled “Artificial Intelligence-Driven Precision Oncology: Integrating Intelligent Technologies with Personalized Cancer Care”.

On behalf of the journal editorial board, we sincerely invite you to submit original high-quality manuscripts to this special issue. Considering your solid academic attainments and influential research achievements in AI and precision oncology, we highly expect to collect your professional views and latest research outcomes.

This issue targets to sort out state-of-the-art AI technologies, and analyze their disruptive value in optimizing precise cancer treatment. Relevant research fields acceptable for submission cover multiple relevant themes, and the journal does not set rigid restrictions on research scopes.

We welcome the submission of manuscripts of the following two types:

(1) Original Research Articles

(2) Systematic Review Articles

Journal Advantages

·       Unparalleled Visibility: Articles are published on the ScienceDirect platform, which receives over 20 million monthly visits from researchers worldwide.

·       Open Access: All articles are made freely and permanently available to readers worldwide.

·       APC Waiver: The Article Processing Charge (APC) will be waived for manuscripts submitted before December 2026.

Key Direction

·       Artificial Intelligence in Precision Cancer Diagnosis

·       AI-Enabled Molecular Profiling and Biomarker Discovery

·       Artificial Intelligence-Guided Personalized Cancer Therapy

·       Pharmacoeconomics and Precision Medication

·       AI-Powered Anticancer Drug Discovery and Development

·       Challenges and Future Perspectives of AI in Precision Oncology

Submission Email: pmeditor@precision-med.com.cn

Manuscript Submission Link:

https://www2.cloud.editorialmanager.com/prmedi/default2.aspx

We look forward to working with you to advance the field of Precision Medication!

Latest published special issue studies:

AI-driven precision cancer treatment: Multimodal data integration and real-time decision support for personalized oncology medication

Please cite this article as: G. Krishnakumar and K. Elumalai, AI-driven precision cancer treatment: Multimodal data integration and real-time decision support for personalized oncology medication, Precision Medication, https://doi.org/10.1016/j.prmedi.2026.100100